SWEET1A Antibody

What is SWEET1 (SLC50A1) and why is it significant in research?

SWEET1 (Sugar Will Eventually be Exported Transporter 1), also known as SLC50A1 (Solute Carrier Family 50 Member 1), is a glucose transporter protein primarily localized in the Golgi apparatus membrane . It plays a crucial role in mediating sugar transport across cell membranes and may stimulate V(D)J recombination through RAG1 activation . The significance of SWEET1 in research has grown substantially due to its implications in metabolic disorders and cancer biology, particularly hepatocellular carcinoma (HCC), where its upregulation correlates with unfavorable patient prognosis . The SWEET1A antibody enables researchers to detect, quantify, and localize this important protein in various experimental contexts.

How does SWEET1 function in cellular metabolism?

SWEET1 functions as a key player in glucose transport regulation across cellular membranes, particularly in the Golgi complex as part of the vesicular exocytosis pathway . In normal conditions, it facilitates glucose efflux in human intestinal and liver cells . Research indicates that SWEET1 regulates cellular glycolysis, affecting ATP production and lactate levels . When SWEET1 is overexpressed, as observed in certain pathological conditions, cells exhibit increased glucose uptake, elevated ATP production, and enhanced lactate formation, indicating a shift toward glycolytic metabolism . The protein also interacts with TRPV2, a relationship that appears to depend on TRPV2 N-glycosylation and likely occurs intracellularly .

What are the common applications of SWEET1A antibodies in research?

SWEET1A antibodies serve multiple research purposes:

• Western blotting for protein expression analysis in tissues and cell lines

• Immunohistochemistry and immunofluorescence for localization studies

• Immunoprecipitation for protein-protein interaction studies

• Flow cytometry for cell-specific expression analysis

• Chromatin immunoprecipitation for studying protein-DNA interactions

These applications have been particularly valuable in cancer research, where SWEET1 expression has been associated with tumor progression and chemoresistance . Researchers also use these antibodies to investigate SWEET1's role in normal physiological processes, such as glucose homeostasis and cellular metabolism across different tissues.

How does SWEET1 expression affect doxorubicin sensitivity in hepatocellular carcinoma?

Recent studies have revealed a significant relationship between SWEET1 expression and doxorubicin (DOX) resistance in hepatocellular carcinoma (HCC) . Gene Set Enrichment Analysis (GSEA) has demonstrated a correlation between increased SLC50A1 expression and enhanced resistance to DOX . In experimental models, HCC cells with downregulated SLC50A1 exhibit significantly higher apoptosis rates when treated with DOX, whereas cells overexpressing SLC50A1 display decreased apoptosis rates under the same treatment conditions .

The mechanisms underlying this resistance pattern appear to involve SLC50A1's regulation of cellular metabolism. By promoting glycolysis, SLC50A1 may provide cancer cells with metabolic advantages that help them survive chemotherapeutic stress. This metabolic reprogramming is increasingly recognized as a hallmark of cancer that contributes to therapeutic resistance. Understanding the precise molecular pathways through which SLC50A1 confers DOX resistance could potentially inform the development of combination therapies that target both glycolysis and conventional chemotherapeutic approaches.

What structural features of SWEET1 are critical for antibody epitope selection?

The selection of optimal epitopes for SWEET1A antibody production requires careful consideration of several structural aspects:

• SWEET1 is a multi-pass membrane protein located primarily in the Golgi apparatus membrane

• Key functional domains include extrafacial gates, substrate binding pockets, and intrafacial gates

• Highly conserved residues critical for protein function have been identified through mutagenesis studies

Specifically, mutagenesis research has identified several amino acids essential for SWEET1 function, including those in the extrafacial gate (Y57, G58, V188, G131), the substrate binding pocket (N73, N192, W176, P191), and the intrafacial gate (P23, P43, P145, P162, F87, Q202, M161) . Amino acid substitutions at these positions abolished or significantly reduced glucose transport activity .

When developing antibodies against SWEET1, researchers should target epitopes that:

• Are accessible in the protein's native conformation

• Avoid highly conserved functional domains if antibody binding might interfere with functional studies

• Consider species-specific variations if cross-reactivity is desired or should be avoided

• Avoid regions subject to post-translational modifications unless specifically targeting modified forms

How has the evolutionary conservation of SWEET1 affected antibody development strategies?

The evolutionary conservation of SWEET1 presents both challenges and opportunities for antibody development . Large-scale sequence analyses have revealed that SWEET transporters are widely distributed across archaea, bacteria, and eukaryotes . This conservation reflects the fundamental importance of sugar transport in cellular life.

Research has shown that human SWEET1 shares significant homology with orthologs from other species—for example, goat SWEET1 DNA and amino acid sequences are 85% and 83% identical to human SWEET1, respectively . This high degree of conservation means:

• Researchers must carefully select epitopes that balance specificity with cross-reactivity

• Highly conserved functional domains may yield antibodies with broader species reactivity

• Species-specific regions should be targeted when developing antibodies for use in models with endogenous SWEET1 expression

Evolutionary analyses using Sequence Similarity Networks (SSN) and phylogenetic tree approaches have identified regions that have undergone differential selection pressure . These analyses suggest that gene fusion, duplication, and horizontal gene transfer have been critical forces driving SWEET protein evolution . When developing antibodies, targeting less conserved regions can provide species specificity, while targeting highly conserved regions can yield tools useful across multiple model organisms.

What are the optimal sample preparation methods for SWEET1 detection using antibodies?

The optimal sample preparation for SWEET1 detection depends on the experimental approach. Based on available research data, the following protocols yield reliable results:

For Western Blotting:

• Harvest tissues or cells and homogenize in ice-cold RIPA buffer supplemented with protease inhibitors

• For membrane-bound SWEET1, include 1% NP-40 or Triton X-100 in the lysis buffer

• Perform protein extraction at 4°C with gentle agitation for 30 minutes

• Centrifuge at 14,000g for 15 minutes at 4°C

• Collect the supernatant and determine protein concentration

• Add sample buffer containing reducing agent and heat at 70°C (not boiling) for 10 minutes

• Load 20-50μg of protein per lane for optimal detection

For Immunohistochemistry:

• Fix tissues in 10% neutral buffered formalin for 24-48 hours

• Process and embed in paraffin

• Section at 4-6μm thickness

• Perform heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

• Block endogenous peroxidase with 3% H₂O₂

• Employ protein blocking with 5% normal serum

• Incubate with SWEET1A antibody at optimized dilution (typically 1:100-1:500) overnight at 4°C

For Cell-Based Assays:

• Fix cells with 4% paraformaldehyde for 15 minutes at room temperature

• Permeabilize with 0.1% Triton X-100 for intracellular staining

• Block with 3% BSA for 1 hour

• Incubate with primary antibody at optimized concentration

What validation techniques ensure SWEET1A antibody specificity in experimental systems?

Ensuring antibody specificity is crucial for reliable research outcomes. The following validation techniques are recommended for SWEET1A antibodies:

• Genetic Knockdown/Knockout Controls:

  • Compare antibody signals between wild-type samples and those with SWEET1 knockdown (siRNA/shRNA) or knockout (CRISPR-Cas9)

  • A specific antibody will show significantly reduced signal in knockdown/knockout samples

• Overexpression Systems:

  • Compare antibody reactivity in cells with normal vs. overexpressed SWEET1

  • Specific antibodies will show increased signal proportional to overexpression

• Peptide Competition Assays:

  • Pre-incubate antibody with the immunizing peptide before application

  • Specific binding will be blocked, resulting in diminished or absent signal

• Multiple Antibody Validation:

  • Use antibodies targeting different epitopes of SWEET1

  • Consistent results with multiple antibodies increase confidence in specificity

• Western Blot Migration Pattern:

  • SWEET1 should appear at approximately the expected molecular weight

  • Verify band shifts with glycosylation-modifying treatments, as SWEET1 interacts with glycosylated proteins

• Mass Spectrometry Confirmation:

  • Immunoprecipitate SWEET1 using the antibody

  • Confirm identity via mass spectrometry analysis

How can researchers quantify SWEET1 expression levels across different experimental conditions?

Accurate quantification of SWEET1 expression is essential for comparative studies. Based on current research methodologies, the following approaches are recommended:

ELISA-Based Quantification:

• Commercial ELISA kits for SWEET1/SLC50A1 provide sensitive detection ranges (e.g., 0.156-10ng/ml) with high sensitivity (0.094ng/mL)

• Sandwich ELISA methodology ensures specificity for natural and recombinant SWEET1

• Appropriate for serum, plasma, tissue homogenates, and cell culture supernatants

Western Blot Densitometry:

• Run samples alongside a concentration gradient of recombinant SWEET1 protein

• Normalize band intensities to loading controls (β-actin, GAPDH)

• Use digital imaging and analysis software for quantification

• Compare relative expression levels across conditions

RT-qPCR for Transcriptional Analysis:

• Extract total RNA using appropriate isolation methods

• Synthesize cDNA using reverse transcription

• Perform qPCR with SWEET1-specific primers

• Normalize to stable reference genes (validated in your experimental system)

• Calculate relative expression using the 2^-ΔΔCT method

Immunohistochemistry Scoring:

• Use digital pathology platforms for quantitative analysis

• Score staining intensity (0-3+) and percentage of positive cells

• Calculate H-score (0-300) by multiplying intensity by percentage

• Compare scores across different experimental conditions

What are common causes of non-specific binding when using SWEET1A antibodies?

Researchers frequently encounter non-specific binding issues when working with SWEET1A antibodies. The most common causes and their solutions include:

In addition, consider the known interaction between SWEET1 and TRPV2, which depends on N-glycosylation . This interaction may affect antibody binding in certain contexts, especially if the epitope is near the interaction site. Using protein-specific blockers (like milk proteins for Western blots) rather than generic blockers can also reduce non-specific binding when working with membrane proteins like SWEET1.

How can researchers overcome challenges in detecting low-abundance SWEET1 in normal tissues?

SWEET1 detection in normal tissues presents challenges due to relatively low expression levels compared to pathological conditions such as HCC, where it is significantly upregulated . To overcome these challenges:

• Signal Amplification Strategies:

  • Use tyramide signal amplification (TSA) for immunohistochemistry

  • Employ enhanced chemiluminescence (ECL) substrates for Western blotting

  • Consider quantum dot-conjugated secondary antibodies for fluorescence studies

• Sample Enrichment Techniques:

  • Perform subcellular fractionation to concentrate Golgi membrane proteins

  • Use immunoprecipitation to enrich SWEET1 before detection

  • Apply ultracentrifugation to isolate membrane fractions

• Sensitive Detection Methods:

  • Utilize droplet digital PCR for low-abundance transcript detection

  • Consider proximity ligation assay (PLA) for protein detection with single-molecule sensitivity

  • Use advanced mass spectrometry with multiple reaction monitoring (MRM)

• Optimized Protocols:

  • Increase protein loading (50-100μg) for Western blots

  • Extend primary antibody incubation time (overnight at 4°C)

  • Reduce washing stringency while maintaining specificity

  • Use signal enhancers appropriate for your detection system

• Consider Alternative Models:

  • Use cell lines with defined SWEET1 expression levels as positive controls

  • Compare detection in tissues known to have higher SWEET1 expression

What strategies help distinguish between different isoforms or modified forms of SWEET1?

Distinguishing between SWEET1 isoforms or post-translationally modified forms requires specialized approaches:

• Isoform-Specific Antibodies:

  • Develop antibodies targeting unique regions in specific isoforms

  • Validate specificities using recombinant proteins of each isoform

• Electrophoretic Separation:

  • Use high-percentage (10-15%) SDS-PAGE gels for improved resolution

  • Consider Phos-tag™ acrylamide gels to separate phosphorylated forms

  • Employ 2D gel electrophoresis (isoelectric focusing followed by SDS-PAGE)

• Enzymatic Treatments:

  • Treat samples with appropriate glycosidases to remove N-linked or O-linked glycans

  • Use phosphatases to remove phosphate groups

  • Compare migration patterns before and after treatment

• Mass Spectrometry Analysis:

  • Employ bottom-up proteomics to identify specific modified residues

  • Use top-down proteomics for intact protein analysis

  • Apply selected reaction monitoring (SRM) for quantification of specific forms

• Combination Approaches:

  • Use co-immunoprecipitation with isoform-specific antibodies followed by detection with antibodies recognizing post-translational modifications

  • Apply proximity ligation assays with antibody pairs targeting specific modifications and total protein

• Genetic Models:

  • Generate expression constructs for individual isoforms as reference standards

  • Create point mutations at known modification sites to serve as negative controls